Mounjaro Korea approval adds heart risk and pediatric diabetes uses

South Korea's drug regulator has widened the label of Eli Lilly's tirzepatide in two directions at once. The Mounjaro Korea approval, granted by the Ministry of Food and Drug Safety (MFDS) on Thursday 22 October 2026, adds cardiovascular risk reduction for adults with type 2 diabetes and established heart disease, plus blood sugar control for children aged 10 and older. Lilly Korea announced the change on Monday 26 October. The heart claim rests on a trial that showed tirzepatide was no worse than an older GLP-1 drug, not that it was better.

What the MFDS Approved for Mounjaro in Korea

The Mounjaro Korea approval lets doctors use the drug to lower the risk of major adverse cardiovascular events, or MACE, in adults who have both type 2 diabetes and established cardiovascular disease. In this label, MACE covers three outcomes: death from cardiovascular causes, a nonfatal heart attack and a nonfatal stroke. The second indication covers children aged 10 and older with type 2 diabetes, where the drug is used together with diet and exercise to improve blood glucose control. Lilly Korea, the local arm of the Indianapolis drugmaker, disclosed both decisions four days after the agency signed off, according to Korea Biomedical Review. The report did not give any figure for how many Korean patients fall into either group.

Mounjaro has collected indications in Korea at a steady pace. After a first MFDS clearance in June 2023 for adults with type 2 diabetes, the label gained a weight management use in July 2024, then a sleep apnea use for adults with obesity whose condition is moderate or severe in August 2025. The October 2026 decision is the fourth step in a little over three years, and the first to reach patients younger than 18. Tirzepatide acts on two gut hormone receptors, GIP and GLP-1. Unlike semaglutide, whose backbone is grown in yeast, it is built by chemistry from the start, so its supply depends on synthetic peptide plants rather than on fermentation tanks. The timeline below sets out each Korean step as reported.

SURPASS CVOT Data Behind the Heart Claim

The case for tirzepatide cardiovascular risk reduction rests on SURPASS-CVOT, a Phase 3 trial that pitted the drug against Trulicity (dulaglutide), an older Lilly GLP-1 receptor agonist that already carries proven heart benefits. The study enrolled more than 13,000 adults with type 2 diabetes and established cardiovascular disease in 30 countries and tracked them for over four and a half years. Using an active comparator instead of a placebo set a hard bar, because any gain had to come on top of a drug already known to protect the heart. The main goal was narrower than a win: to show that tirzepatide was not worse than dulaglutide at preventing MACE, a design called noninferiority.

Tirzepatide met that goal with a hazard ratio of 0.92, but the 95.3 percent confidence interval ran from 0.83 to 1.01, so superiority was not shown.

Tirzepatide met that goal with a hazard ratio of 0.92, but the 95.3 percent confidence interval ran from 0.83 to 1.01, so superiority was not shown. In plain terms, the point estimate means about 8 percent fewer events than with dulaglutide, yet the range still includes no difference at all. Lilly's topline report, as covered by the medical outlet HCPLive, also cited a 16 percent lower rate of death from any cause, a secondary result the trial was not designed to prove on its own. Gastrointestinal side effects were the most common problems with tirzepatide. The Korean report said most were mild to moderate, clustered during dose escalation and eased over time during the long follow up. The report did not break out side effect rates for each arm.

Pediatric Type 2 Diabetes Joins the Korean Label

The second change opens tirzepatide to pediatric type 2 diabetes in children aged 10 and older, a group outside every earlier Korean indication listed in the report. The use is limited to improving blood glucose control alongside diet and exercise, the same framing the drug carried for adults when it first arrived in 2023. The Korean coverage did not name the study behind the pediatric decision, and it gave no figures on how many children might be treated. Readers should not assume the adult heart findings carry over to this group. The two new indications rest on separate evidence in separate patients, and the cardiovascular claim applies only to adults who already have established cardiovascular disease.

Kim Sung-rae, chair of the Korean Diabetes Association and an endocrinologist at Bucheon St. Mary's Hospital of the Catholic University of Korea, commented on the adult heart indication. In his view, doctors treating these patients can now set heart protection as a treatment goal next to sugar and weight control, rather than weighing those aims one at a time. His comment ties the label to clinic decisions: a Korean doctor can now point to a domestic indication, not only to foreign trial data. The comparator still matters. Because dulaglutide already had heart benefits, the trial does not show tirzepatide beats every option, only that it held its own while, per Lilly's topline results, lowering blood sugar and weight further.

National Health Insurance Coverage Is the Next Test

Approval and payment are separate steps in Korea. The MFDS rules on whether a medicine is safe and effective for a use, while public reimbursement follows its own review and price talks. Seiya Komatsu, who heads Lilly Korea, said the company plans to seek National Health Insurance coverage and will cooperate with officials and other parties on wider patient access. That statement is a plan, not a result. The report did not say which Mounjaro uses, if any, are reimbursed today, and it gave no timetable or price for the new indications. Until a payer decision arrives, this Mounjaro Korea approval changes what doctors may prescribe, not what patients will pay.

The decision also lands as Korean drugmakers pursue their own incretin products. Daewon Pharmaceutical, for example, has reported that its oral semaglutide candidate reached higher exposure than Rybelsus in two small studies, data that remain unpublished. Abroad, semaglutide copies are spreading, and our semaglutide patent expiry map tracks approved generics in India, Canada and Brazil. Against that backdrop, a formal heart indication gives Lilly a clinical argument to bring into any coverage talks in Korea. How much weight the payer gives a noninferiority result, rather than a superiority result, is the open question for the months ahead, and the report named no date for it.

Conclusion

The Mounjaro Korea approval widens tirzepatide's label to adults with type 2 diabetes and heart disease and to children aged 10 and older. The heart claim rests on SURPASS-CVOT, where tirzepatide matched dulaglutide on major cardiovascular events but did not beat it. What happens next depends less on the MFDS than on payers: Lilly Korea says it will seek National Health Insurance coverage, and no timetable has been given. Until then, the reach of the new uses will track reimbursement.